Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.67 USD | +0.35% | +0.12% | +26.70% |
Financials (USD)
Sales 2024 * | 3.63M | Sales 2025 * | 6.18M | Capitalization | 1.33B |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -191M | EV / Sales 2024 * | 227 x |
Net cash position 2024 * | 502M | Net cash position 2025 * | 403M | EV / Sales 2025 * | 149 x |
P/E ratio 2024 * |
-8.46
x | P/E ratio 2025 * |
-8.69
x | Employees | 171 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.5% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | +0.35% | ||
1 week | +0.12% | ||
Current month | +7.27% | ||
1 month | -4.04% | ||
3 months | -5.83% | ||
6 months | +132.73% | ||
Current year | +26.70% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | 51 | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 14 M€ | -2.69% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 25.64 | +0.23% | 526,900 |
24-05-15 | 25.58 | -0.66% | 429,968 |
24-05-14 | 25.75 | +0.70% | 425,599 |
24-05-13 | 25.57 | -0.51% | 593,875 |
24-05-10 | 25.7 | +0.23% | 397,446 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.70% | 1.33B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+50.30% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- FDMT Stock